Menu Search
Equities

Rapid Nutrition PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0RNS:LSE

Rapid Nutrition PLC

Actions
  • Price (EUR)11.76
  • Today's Change11.76 / --
  • Shares traded333.00
  • 1 Year change-32.41%
  • Beta-0.8410
Data delayed at least 20 minutes, as of Feb 06 2026 16:54 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Rapid Nutrition PLC is a United Kingdom-based natural healthcare company focused on the research, development and production of a range of evidence-based nutrition. The Company is engaged in the development and distribution of science-based health and wellness brands across the globe. The Company's core business is the creation of organic and natural scientific-based health food supplements and building them into brands. Its flagship brands include System LS and Azurene. System LS includes six products. Each product provides natural and organic ingredients designed to support weight loss. Further, the products include a phone application, which offers ongoing motivation for consumers. Azurene is a patented blend of herbs traditionally used in Western, Ayurvedic and Chinese herbal medicine for symptoms of sore throat, colds and flu, as well as added Ashwagandha and Andrographis for immunity boost for travelers.

  • Revenue in EUR (TTM)449.47k
  • Net income in EUR-1.53m
  • Incorporated2012
  • Employees12.00
  • Location
    Rapid Nutrition PLCSuite A, 82 James Carter RoadMILDENHALL IP28 7DEUnited KingdomGBR
  • Phone+44 208 040 3498
  • Websitehttps://www.rnplc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.